Topic: Clinical Trial Results
Esperion’s phase 3 results of bempedoic acid showed it lowered cholesterol levels, but 13 deaths were also reported, causing shares to slide.
The study found the wearable device was no more effective than medication alone at reducing sudden cardiac death.
Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.
Almost 30% of the participants were alive 18 months after starting treatment on a combination of CCX872 and the chemotherapy regimen FOLFIRINOX.
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.
The IL-23 antibody easily outperformed J&J’s Stelara and AbbVie’s own Humira, setting it up to go before regulators next year.
The study linked synthetic oral endocannabinoid-mimetic anabasum to a statistically significant drop on a skin disease scale.
The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.
The data tee Motif Bio up to file for approval of a drug that was knocked back by the FDA in 2009 and almost sunk the biotech 12 months ago.
The trial linked the single-domain antibody to a significant drop in time to platelet count response, bolstering Ablynx’s pitch for approval.